

Global Atrial Fibrillation Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

<https://marketpublishers.com/r/G570E219070EN.html>

Date: August 2019

Pages: 93

Price: US\$ 1,799.00 (Single User License)

ID: G570E219070EN

Abstracts

High levels of pipeline activity are being observed in Atrial Fibrillation treatment during 2019. Clinical development activities are being undertaken by more than 20 companies including Acesion Pharma, Aetas Pharma, Allergan Plc, Allosteros Therapeutics Inc, AnaBios Corporation and others.

A Significant contribution to the Atrial Fibrillation pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Atrial Fibrillation pipeline included 23 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Atrial Fibrillation condition and increased access to investments is encouraging growth of Atrial Fibrillation drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Atrial Fibrillation drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Atrial Fibrillation therapeutic candidates. Further, drugs in clinical stage including phase 1,

phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Atrial Fibrillation pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Atrial Fibrillation. Further, orphan drug status, fast track designation, grants awarded and other special status for Atrial Fibrillation pipeline compounds are also included. This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Atrial Fibrillation pipeline and formulate effective research and development strategies.

RESEARCH METHODOLOGY

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Atrial Fibrillation Pipeline candidates-

Pre-clinical Phase: Discovery, research, pre-clinical

Early Phase: Phase 1 and Phase 2 Atrial Fibrillation drugs

Late phase: Phase 3 and in-approval Atrial Fibrillation drugs

Companies involved in the Pipeline-

Company overview

Snapshot

Atrial Fibrillation therapeutic treatment activities

Details for each Atrial Fibrillation drug candidate-

Snapshot

Drug Name

Alternative Names

Company

Originator

Phase

Molecule Type

Orphan Drug Status

Drug Overview

Mechanism of Action

Current Status

Trial Details

Other details

Pre-clinical trials for each drug candidate

Clinical trials for each drug candidate

Recent Atrial Fibrillation therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news

Contents

1 TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2 EXECUTIVE SUMMARY

- 2.1 Atrial Fibrillation- Disease Overview
- 2.2 Atrial Fibrillation- Pipeline Snapshot
- 2.3 Atrial Fibrillation- Pipeline Drugs by Phase
- 2.4 Atrial Fibrillation- Pipeline Drugs by Company
- 2.5 Atrial Fibrillation- Pipeline Drugs by Mechanism of Action

3 COMPANY WISE PIPELINE ANALYSIS

- 3.1 Acesion Pharma Atrial Fibrillation Drug Pipeline, H2- 2019
- 3.2 Aetas Pharma Atrial Fibrillation Drug Pipeline, H2- 2019
- 3.3 Allergan Plc Atrial Fibrillation Drug Pipeline, H2- 2019
- 3.4 Allosteros Therapeutics Inc Atrial Fibrillation Drug Pipeline, H2- 2019
- 3.5 AnaBios Corporation Atrial Fibrillation Drug Pipeline, H2- 2019
- 3.6 ARCA biopharma Inc Atrial Fibrillation Drug Pipeline, H2- 2019
- 3.7 Armaron Bio Pty Ltd Atrial Fibrillation Drug Pipeline, H2- 2019
- 3.8 Boston Pharmaceuticals Inc Atrial Fibrillation Drug Pipeline, H2- 2019
- 3.9 Correvio Pharma Corp. Atrial Fibrillation Drug Pipeline, H2- 2019
- 3.10 Dong-A Socio Holdings Co Ltd Atrial Fibrillation Drug Pipeline, H2- 2019
- 3.11 Espero BioPharma Inc Atrial Fibrillation Drug Pipeline, H2- 2019
- 3.12 G3 Pharmaceuticals Inc Atrial Fibrillation Drug Pipeline, H2- 2019
- 3.13 Gilead Sciences Inc Atrial Fibrillation Drug Pipeline, H2- 2019
- 3.14 HUYA Bioscience International Atrial Fibrillation Drug Pipeline, H2- 2019
- 3.15 InCarda Therapeutics Inc Atrial Fibrillation Drug Pipeline, H2- 2019
- 3.16 Merck & Co Inc Atrial Fibrillation Drug Pipeline, H2- 2019
- 3.17 Milestone Pharmaceuticals Inc Atrial Fibrillation Drug Pipeline, H2- 2019
- 3.18 Nissan Chemical Industries Ltd Atrial Fibrillation Drug Pipeline, H2- 2019
- 3.19 OMEICOS Therapeutics GmbH Atrial Fibrillation Drug Pipeline, H2- 2019
- 3.20 Rhythm Therapeutics Inc Atrial Fibrillation Drug Pipeline, H2- 2019
- 3.21 The Geneva Biotech Center SA Atrial Fibrillation Drug Pipeline, H2- 2019
- 3.22 Toa Eiyo Ltd Atrial Fibrillation Drug Pipeline, H2- 2019

3.23 Verseon Corp Atrial Fibrillation Drug Pipeline, H2- 2019

4 PHASE 1 PIPELINE DRUG DETAILS

- 4.1 Atrial Fibrillation- Phase 1 Drug Details
- 4.2 Atrial Fibrillation- Phase 1 Drug Overview
- 4.3 Atrial Fibrillation- Phase 1 Mechanism of Action
- 4.4 Current Status
- 4.5 Trial Details

5 PHASE 2 PIPELINE DRUG DETAILS

- 5.1 Atrial Fibrillation- Phase 2 Drug Details
- 5.2 Atrial Fibrillation- Phase 2 Drug Overview
- 5.3 Atrial Fibrillation- Phase 2 Mechanism of Action
- 5.4 Current Status
- 5.5 Trial Details

6 PHASE 3 PIPELINE DRUG DETAILS

- 6.1 Atrial Fibrillation- Phase 3 Drug Details
- 6.2 Atrial Fibrillation- Phase 3 Drug Overview
- 6.3 Atrial Fibrillation- Phase 3 Drug Mechanism of Action
- 6.4 Current Status
- 6.5 Trial Details

7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS

- 7.1 Atrial Fibrillation- Pre-clinical Phase Drug Details
- 7.2 Atrial Fibrillation- Pre-clinical Phase Drug Overview
- 7.3 Atrial Fibrillation- Pre-clinical Phase Drug Mechanism of Action
- 7.4 Current Status
- 7.5 Trial Details

8 RECENT NEWS AND DEVELOPMENTS

9 APPENDIX

- 9.1 About VPAResearch

9.2 Sources and Research Methodology

I would like to order

Product name: Global Atrial Fibrillation Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

Product link: <https://marketpublishers.com/r/G570E219070EN.html>

Price: US\$ 1,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G570E219070EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

